Mark Coyne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark Coyne has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Emer Joyce
Department of Cardiology, Mater Misericordiae University Hospital, Eccles Street Dublin 7, Ireland; UCD School of Medicine, UCD Health Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland
1 shared publication - Gerard Giblin
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Joseph Patrick Morris
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Katie Hewitt
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
1 shared publication - Katie Murphy
Cardiology Department, Mater Misericordiae University Hospital, Eccles St., D07 R2WY Dublin, Ireland
1 shared publication - Michael Alexander
Department of Clinical Neurophysiology, Tallaght University Hospital, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 11 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002906
Spectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network
Background: Variant transthyretin amyloidosis (ATTRv) is a hereditary multisystem disorder with clinical spectrum ranging from predominant cardiomyopathy to polyneuropathy. In the Irish population, the T60A mutation has been previously recognised as the most common genotype. Objectives: The aim of this study is to describe the diagnostic and phenotypic spectrum of patients with T60A ATTRv attending an Irish Expert Amyloidosis Network. Methods: In this observational study design, the medical, laboratory and radiological records of patients enrolled in our amyloidosis registry with a confirmed genotype diagnosis of T60A ATTRv were reviewed. Results: A cohort of 24 patients (12 female) met criteria for inclusion. The median age at diagnosis was 65 years (IQR 59.5–66.5) and median follow-up 44 months (IQR 31–58). Carpal tunnel syndrome was the initial manifestation in almost half (46%) of patients. Overall, a mixed cardioneuro phenotype was demonstrated including autonomic (75%), small (58%) and large fibre (46%) neuropathy largely predating a cardiac phenotype consisting of heart failure (63%), atrial arrhythmia (42%) and bradycardia (13%). Conclusion: The contemporary clinical spectrum of T60A ATTRv in Ireland is one of patients typically presenting in the seventh decade with an already manifest neuropathy phenotype, largely predating a cardiac phenotype dominated by heart failure.
- 11 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002906
Open AccessSpectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network
Background: Variant transthyretin amyloidosis (ATTRv) is a hereditary multisystem disorder with clinical spectrum ranging from predominant cardiomyopathy to polyneuropathy. In the Irish population, the T60A mutation has been previously recognised as the most common genotype. Objectives: The aim of this study is to describe the diagnostic and phenotypic spectrum of patients with T60A ATTRv attending an Irish Expert Amyloidosis Network. Methods: In this observational study design, the medical, laboratory and radiological records of patients enrolled in our amyloidosis registry with a confirmed genotype diagnosis of T60A ATTRv were reviewed. Results: A cohort of 24 patients (12 female) met criteria for inclusion. The median age at diagnosis was 65 years (IQR 59.5–66.5) and median follow-up 44 months (IQR 31–58). Carpal tunnel syndrome was the initial manifestation in almost half (46%) of patients. Overall, a mixed cardioneuro phenotype was demonstrated including autonomic (75%), small (58%) and large fibre (46%) neuropathy largely predating a cardiac phenotype consisting of heart failure (63%), atrial arrhythmia (42%) and bradycardia (13%). Conclusion: The contemporary clinical spectrum of T60A ATTRv in Ireland is one of patients typically presenting in the seventh decade with an already manifest neuropathy phenotype, largely predating a cardiac phenotype dominated by heart failure.